Laddar...
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cytotoxic chemotherapy alone. This treatment provided only modest survival benefit. The introduction of immune checkpoint inhibitors targeting prog...
Sparad:
| I publikationen: | Lung Cancer (Auckl) |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6556538/ https://ncbi.nlm.nih.gov/pubmed/31239797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S176391 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|